Clinical Trials Browser

Phase 3 × INDUSTRY × niraparib × Clear all

NCT04497844 2026-05-11

AMPLITUDE

Phase 3 Active not recruiting

696 enrolled 15 charts 1 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT03748641 2026-05-08

MAGNITUDE

Phase 3 Active not recruiting

765 enrolled 16 charts 1 FDA

Prostatic Neoplasms, Castration-Resistant

NCT06915025 2026-05-04

OVATION-3

Phase 3 Recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04475939 2026-05-01

ZEAL-1L

Phase 3 Completed

666 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT03768063 2026-04-28

IMbrella B

Phase 3 Active not recruiting

Neoplasms

NCT02655016 2026-03-10

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Phase 3 Active not recruiting

733 enrolled 21 charts 1 FDA

Ovarian Neoplasms

NCT03602859 2025-12-31

FIRST

Phase 3 Active not recruiting

1,400 enrolled 18 charts

Ovarian Neoplasms

NCT03981796 2025-09-03

RUBY

Phase 3 Active not recruiting

785 enrolled 2 FDA

Neoplasms, Recurrence

NCT04915755 2025-07-16

ZEST

Phase 3 Active not recruiting

40 enrolled 13 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01847274 2023-06-02

A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

Phase 3 Completed

596 enrolled 65 charts

Ovarian Neoplasms

NCT01905592 2022-11-15

BRAVO

Phase 3 Terminated

216 enrolled 19 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms